Search Within

Komal Lachhman Jhaveri

Formats
  1. Meeting Abstract (120)
  2. Journal Article (89)
  3. Review (7)
  4. Editorial (2)
  5. Correspondence (1)
  6. Guidelines (1)
Groups
  1. Breast Medicine Service (220)
  2. Department of Medicine (220)
  3. Solid Tumor Oncology Division (220)
  4. GSK Faculty (58)
  5. Survivorship Research (47)
  6. Epidemiology and Biostatistics (44)

More Groups

People
  1. Shanu Modi (35)
  2. Sarat Chandarlapaty (28)
  3. Pedram Razavi (25)
  4. Clifford Hudis (24)
  5. Sujata Patil (22)
  6. Gary Ulaner (18)

More People

Years
  1. 2025 (26)
  2. 2024 (34)
  3. 2023 (17)
  4. 2022 (24)
  5. 2021 (26)
  6. 2020 (28)

More Years

Publications
  1. Journal of Clinical Oncology (66)
  2. Cancer Research (33)
  3. Annals of Oncology (22)
  4. Clinical Cancer Research (10)
  5. European Journal of Cancer (5)
  6. New England Journal of Medicine (5)

More Publications

Publishers
  1. American Society of Clinical Oncology (69)
  2. American Association for Cancer Research (47)
  3. Oxford University Press (23)
  4. Elsevier Inc. (18)
  5. Springer (7)
  6. Nature Publishing Group (6)

More Publishers

Results (220)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • DESTINY-Breast07: Dose-expansion interim analysis of T-DXd monotherapy and T-DXd + pertuzumab in patients with previously untreated HER2+ mBC
    Meeting Abstract

    Andre, F.; Hamilton, E. P.; Loi, S.; Anders, C. K.; Schmid, P.; Stroyakovskiy, D.; Villanueva, R.; Pedrini, J. L.; Doval, D. C.; Zurawski, B.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Comparison of expert treatment recommendations versus community healthcare providers: Analysis from an online decision support tool for metastatic breast cancer
    Meeting Abstract

    Mayer, E. L.; Jhaveri, K. L.; Hamilton, E. P.; Kalinsky, K.; Constanzo, J. D.; Rosenthal, K. M.; Spring, L.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Real-world (RW) risk of recurrence among patients (pts) diagnosed with stage II-III HR+/HER2-early breast cancer (EBC) treated with endocrine therapy (ET) in the US
    Meeting Abstract

    Razavi, P.; Ahmed, M.; Roush, A.; Parikh, R.; Hitchens, A.; Shen, S.; Safonov, A.; Jhaveri, K. L.; Robson, M. E.; Peacock, N. W.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Overall survival analysis of first line CDK4/6 inhibitors in a large real-world cohort of patients with hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer
    Meeting Abstract

    Ferraro, E.; Moiso, E.; Safonov, A.; Cabel, L.; Loudon, L.; Dang, C. T.; Shen, S.; Jhaveri, K. L.; Robson, M. E.; Chandarlapaty, S.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Predicting CDK4/6 inhibitors outcomes in pts with HR+/HER2-metastatic breast cancer: A machine learning approach
    Meeting Abstract

    Moiso, E.; Ferraro, E.; Cabel, L.; Safonov, A.; Ahmed, M.; An, J. A. R.; Jhaveri, K. L.; Norton, L.; Robson, M. E.; Modi, S.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Sequential use of PI3K/AKT/mTOR pathway inhibitors alpelisib and everolimus in patients with hormone receptor-positive (HR+) metastatic breast cancer
    Meeting Abstract

    Shen, S.; Safonov, A.; Bromberg, M.; Chen, Y.; Ahmed, M.; Razavi, P.; Jhaveri, K. L.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): Patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial
    Journal Article

    Oliveira, M.; Rugo, H. S.; Howell, S. J.; Dalenc, F.; Cortes, J.; Gomez, H. L.; Hu, X.; Toi, M.; Jhaveri, K.; Krivorotko, P.; more...
    Lancet Oncology (2024)

    Fulltext@MSK | Save
  • TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2- breast cancer
    Journal Article

    Bardia, A.; Jhaveri, K.; Kalinsky, K.; Pernas, S.; Tsurutani, J.; Xu, B.; Hamilton, E.; Im, S. A.; Nowecki, Z.; Sohn, J.; more...
    Future Oncology (2024)

    Fulltext@MSK | Save
  • Phase Ia/b study of giredestrant ± palbociclib and ± luteinizing hormone-releasing hormone agonists in estrogen receptor-positive, HER2-negative, locally advanced/metastatic breast cancer
    Journal Article

    Jhaveri, K. L.; Bellet, M.; Turner, N. C.; Loi, S.; Bardia, A.; Boni, V.; Sohn, J.; Neilan, T. G.; Villanueva-Vázquez, R.; Kabos, P.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • Current and emerging treatment approaches for hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer
    Review

    Jhaveri, K.; Marmé, F.
    Cancer Treatment Reviews (2024)

    Fulltext@MSK | Save